ONWARD Medical reports 31 participants enrolled in its pivotal spinal cord stimulation trial
The company's third-quarter update also reported €2.5 million in revenue, 88 ARC-EX systems sold or supplied, and first implants in two smaller ARC-IM feasibility studies.
ONWARD Medical said on November 3 that 31 participants have enrolled in Empower BP, its randomized, sham-controlled pivotal study of the implanted ARC-IM system for blood pressure instability after spinal cord injury, with 16 sites recruiting in the US, Canada and Germany. The company also reported first implants in the EIGER mobility study and first-in-human use in the ReeVoid bladder-control study, both feasibility work in Switzerland. Third-quarter revenue was €2.5 million, including €2.0 million from its non-invasive ARC-EX system; 88 units were sold or supplied through paid evaluations, up 120% in units from a year earlier.
These figures are company-reported, and no efficacy data from the trials were included. ARC-IM remains investigational.
Learn more: Spinal cord stimulation